在β-粉胺依赖的病理生理学中,D-氨酸的早期参与
J-M Billard1,2, E Ploux3, S Largilliere3
1Normandie University, UNICAEN, INSERM, GIP CYCERON, COMETE, Caen, France. jean-marie.billard@inserm.fr.
Cellular and molecular life sciences : CMLS
|April 28, 2025
概括
在阿尔茨海默氏病 (AD) 中,β-粉胺通过D-氨酸破坏N-甲基-D-酸盐受体 (NMDAR) 功能,损害记忆力. 在AD模型中减少D-氨酸可以减轻这些突触和认知缺陷.
科学领域:
- 神经科学是一个神经科学.
- 神经退行性疾病 神经退行性疾病
- 分子生物学分子生物学
背景情况:
- N-甲基-D-酸盐受体 (NMDARs) 对于学习和记忆至关重要,需要谷氨酸和共激素D-氨酸来激活.
- 已知在阿尔茨海默病 (AD) 中积累的β-粉样蛋白 (Aß) 在体外影响D-胺依赖的NMDAR激活,但它们在体内对AD病理生理学的贡献尚不清楚.
研究的目的:
- 在阿尔茨海默病小鼠模型中研究D-氨酸在Aß诱导的NMDAR功能障碍和认知缺陷中的体内作用.
- 为了确定调节D-氨酸水平是否可以改善AD相关的突触和记忆障碍.
主要方法:
- 从5xFAD小鼠 (一种AD模型) 的海马片中进行电生理学记录,以评估突触功能和依赖NMDAR的长期潜能.
- 在5xFAD小鼠中进行行为测试以评估工作记忆,空间记忆和认知灵活性,这些小鼠具有或没有赛林赛马酶 (D-赛林合成酶) 的遗传删除.
主要成果:
- 5xFAD小鼠表现出NMDAR功能下降,NMDAR依赖的长期强化受损,以及基底神经传递发生变化,与早期Aß增加和短暂的D-氨酸升高相关.
- 在5xFAD老鼠中观察到工作记忆,空间记忆和认知灵活性缺陷.
- 在5xFAD小鼠中,血清素种族酶的遗传删除可以防止或减少NMDAR突触放松调节和行为障碍,这表明D-血清素的关键作用.
结论:
- D-氨酸参与了与粉样蛋白积累相关的AD早期病原性机制.
- 向D-氨酸通路可能为AD提供治疗策略,但L-氨酸前体的有效性需要进一步研究.
相关概念视频
03:03Amyloid Fibrils
9.0K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.0K
01:26Alzheimer's Disease: Overview
315
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
315
01:22Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128